UnknownPhase 2/3

Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis

Iran10 participantsStarted 2009-09

Plain-language summary

The purpose of this study is to evaluate the efficacy and side effects of donor hematopoietic cells using chemotherapy regimen without total-body irradiation in children undergoing a hematopoietic stem cell transplant for Malignant infantile osteopetrosis. The blood stem cells will be derived from either related donor or unrelated umbilical cord blood or haploidentical donor.

Who can participate

Age range

5 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of Osteopetrosis confirm by bone biopsy and radiographic imaging * Age up to 5 year old Exclusion Criteria: * Carbonic Anhydrase II (CAII) deficiency osteopetrosis variant * Creatinine clearance ≤ 40ml/min/1.73m\^2 or RTA * Bilirubin ≥ 3mg/dL * SGPT ≥ 500 U/L * Current severe infection * Evidence of CNS involvement * Morbidity such as blindness or deafness

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Overall Survival and Progressive Free Survival in patient with infantile Osteopetrosis who receive allogeneic HSCT

Timeframe: 1 year

Trial details

NCT IDNCT01087398

SponsorTehran University of Medical Sciences

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-11

Contact for this trial

Amir Ali Hamidieh, MD

84902645 aahamidieh@sina.tums.ac.ir

View on ClinicalTrials.gov More Osteopetrosis trials